Scholarlink

Background <p>Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Early detection is critical for improving patient outcomes. This study investigated the potential of circulating tumour DNA (ctDNA) methylation markers, specifically Heart and Neural Crest Derivatives Expressed 2 (HAND2) and Glycoprotein M6A (GPM6A), as novel non-invasive biomarkers for CRC detection and treatment monitoring.</p> Methods <p>Plasma samples were collected from 40 CRC patients before and after treatment, as well as 40 healthy controls. Methylation levels of <i>HAND2</i> and <i>GPM6A</i> in ctDNA were quantified using quantitative methylation-specific PCR (qMS-PCR).</p> Results <p>Methylation levels of <i>HAND2</i> and <i>GPM6A</i> were significantly elevated in pre-treatment colorectal cancer (CRC) patients compared to post-treatment patients and healthy controls. Specifically, <i>HAND2</i> methylation exhibited a statistically significant reduction following therapeutic intervention (pre-treatment: 55.75% ± 26.75 vs. post-treatment: 37.98% ± 22.93, <i>p</i> &lt; 0.001), with no significant correlation observed between pre- and post-treatment levels (Pearson <i>r</i> = 0.1030, <i>p</i> = 0.53). Similarly, <i>GPM6A</i> methylation decreased markedly post-treatment (pre-treatment: 72.93% ± 18.06 vs. post-treatment: 49.48% ± 16.83, <i>p</i> &lt; 0.001) yet demonstrated a statistically significant positive correlation between pre- and post-treatment values (Pearson <i>r</i> = 0.3181, <i>p</i> = 0.05). Receiver operating characteristic (ROC) curve analysis revealed robust diagnostic performance, with the combined <i>HAND2</i> and <i>GPM6A</i> methylation model yielding an area under the curve (AUC) of 0.9213 (95% CI: 0.8569–0.9856, <i>p</i> &lt; 0.001), surpassing the individual discriminative capacities of <i>HAND2</i> (AUC = 0.8906) and <i>GPM6A</i> (AUC = 0.8881). Survival analysis leveraging the Cancer Genome Atlas (TCGA) dataset indicated a potential association between elevated methylation of both genes. It reduced survival probability, with a pronounced effect observed in rectal adenocarcinoma.</p> Conclusion <p><i>HAND2</i> and <i>GPM6A</i> methylation in ctDNA are promising non-invasive biomarkers for CRC detection and monitoring, outperforming the diagnostic accuracy of traditional markers such as CEA or CA19-9. Further research is needed to validate these findings in larger cohorts and investigate their potential as markers for treatment response and disease recurrence.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Non-invasive colorectal cancer biomarkers: HAND2 and GPM6A methylation in circulating tumour DNA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Amir Mahdi Nili,
  • Kamal Mohammadian,
  • Fatemeh Namazi Nanehkaran,
  • Faranak Jamshidian,
  • Arash Moradi,
  • Shahla Mohammad Ganji

摘要

Background

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Early detection is critical for improving patient outcomes. This study investigated the potential of circulating tumour DNA (ctDNA) methylation markers, specifically Heart and Neural Crest Derivatives Expressed 2 (HAND2) and Glycoprotein M6A (GPM6A), as novel non-invasive biomarkers for CRC detection and treatment monitoring.

Methods

Plasma samples were collected from 40 CRC patients before and after treatment, as well as 40 healthy controls. Methylation levels of HAND2 and GPM6A in ctDNA were quantified using quantitative methylation-specific PCR (qMS-PCR).

Results

Methylation levels of HAND2 and GPM6A were significantly elevated in pre-treatment colorectal cancer (CRC) patients compared to post-treatment patients and healthy controls. Specifically, HAND2 methylation exhibited a statistically significant reduction following therapeutic intervention (pre-treatment: 55.75% ± 26.75 vs. post-treatment: 37.98% ± 22.93, p < 0.001), with no significant correlation observed between pre- and post-treatment levels (Pearson r = 0.1030, p = 0.53). Similarly, GPM6A methylation decreased markedly post-treatment (pre-treatment: 72.93% ± 18.06 vs. post-treatment: 49.48% ± 16.83, p < 0.001) yet demonstrated a statistically significant positive correlation between pre- and post-treatment values (Pearson r = 0.3181, p = 0.05). Receiver operating characteristic (ROC) curve analysis revealed robust diagnostic performance, with the combined HAND2 and GPM6A methylation model yielding an area under the curve (AUC) of 0.9213 (95% CI: 0.8569–0.9856, p < 0.001), surpassing the individual discriminative capacities of HAND2 (AUC = 0.8906) and GPM6A (AUC = 0.8881). Survival analysis leveraging the Cancer Genome Atlas (TCGA) dataset indicated a potential association between elevated methylation of both genes. It reduced survival probability, with a pronounced effect observed in rectal adenocarcinoma.

Conclusion

HAND2 and GPM6A methylation in ctDNA are promising non-invasive biomarkers for CRC detection and monitoring, outperforming the diagnostic accuracy of traditional markers such as CEA or CA19-9. Further research is needed to validate these findings in larger cohorts and investigate their potential as markers for treatment response and disease recurrence.